In a Nutshell
Pain during sex (dyspareunia) is one of the most common — and most under-discussed — menopause symptoms.
In perimenopause and postmenopause, a very common cause is GSM from estrogen loss — but it's not the only cause, which is why persistent or focal pain deserves an exam.
When GSM is the driver, treatment is highly effective: lubricants and moisturizers help right away, and low-dose vaginal estrogen, prasterone (Intrarosa), or ospemifene (Osphena) restore tissue health within 8-12 weeks.
Sex should not be persistently painful. If it hurts, that's a medical reason to seek help, not a phase to wait out. This can start in late perimenopause, not just after periods stop completely.
What Painful Sex in Menopause Feels Like
Most women describe the pain as a sharp, burning, or stinging sensation at the vaginal opening (introitus) during initial penetration, often described as "feels like sandpaper" or "being torn." Some women feel deeper pelvic pain on thrusting.
After sex, soreness, burning, or a stinging sensation when urinating may persist for hours.
Common patterns:
- Pain at penetration — usually due to atrophy at the introitus and reduced lubrication
- Friction pain during sex — atrophic tissue is fragile; what used to be neutral friction now causes micro-tears
- Spotting after sex — fragile vaginal tissue can cause light spotting after sex, especially with more advanced atrophy. After menopause, any bleeding or spotting should still be discussed with a clinician
- Deeper pelvic pain — may indicate other causes (uterine prolapse, fibroids, endometriosis, pelvic floor dysfunction)
- Burning during urination after sex — friction can irritate the urethra in atrophic tissue
- Pain that triggers anxiety or avoidance — fear of recurrence creates pelvic floor tension, which worsens the next encounter
The cycle of pain → anxiety → muscle tension → more pain is a major reason early intervention matters. Once the cycle is established, treatment requires both physical (estrogen, dilators, pelvic PT) and psychological (sex therapy, partner communication) components.
Why Painful Sex Happens in Menopause
The dominant cause is vulvovaginal atrophy from estrogen deficiency — the same mechanism that drives vaginal dryness, but functional impact is sex-specific:
- Vaginal lining thinning — what used to be a thick, well-lubricated, multi-layered tissue becomes thinner, drier, and more fragile, tearing and irritating more easily under friction
- Reduced natural lubrication during arousal — even with normal arousal cues, low-estrogen tissue can't produce the transudate that smooths penetration
- Loss of elasticity — the vagina shortens, narrows, and stretches less, so what used to fit comfortably now feels tight or "stuck"
- Altered vaginal pH — increases susceptibility to infections (yeast, BV), which compound discomfort
- Vulvar tissue thinning — labia minora shrink, the introitus narrows, and the tissue becomes more sensitive to pressure and friction
The longer the tissue is estrogen-deprived, the more atrophic it tends to become. GSM often persists or worsens without treatment, unlike hot flashes which often improve for many women over time.
Other contributing or non-menopause causes that can mimic or compound dyspareunia:
- Vulvodynia or vestibulodynia — chronic vulvar pain syndromes that persist despite atrophy treatment
- Pelvic floor dysfunction — overactive or hypertonic pelvic floor muscles causing penetration pain
- Lichen sclerosus or lichen planus — chronic inflammatory skin conditions
- Vaginismus — involuntary muscle spasm of the pelvic floor
- Endometriosis or adenomyosis — usually deeper pain on thrusting
- Uterine fibroids or pelvic prolapse — can cause positional pain
- Past sexual trauma — pelvic floor protection responses
- Yeast or bacterial infections — secondary to atrophy or independent
- Anxiety, depression, relationship distress — affect arousal and tension
- Antidepressant side effects — some antidepressants, especially SSRIs and SNRIs, can contribute to lower desire, reduced arousal, vaginal dryness, or difficulty reaching orgasm
Is This Normal? When to See a Doctor
It's common for women in perimenopause and postmenopause to experience some level of dyspareunia — but common is not the same as normal, and it is not something to accept indefinitely.
WebMD's reviewer puts it directly: "Sex should never hurt. Get an exam to help pinpoint the cause".
Treatment is highly effective. Avoiding sex doesn't treat the underlying atrophy — for some women, ongoing sexual activity or vaginal stimulation may help maintain comfort and flexibility — but GSM is primarily driven by estrogen loss, not by activity level.
Clinical Red Flags — Do NOT Assume It's Just Menopause
Painful sex deserves an evaluation that rules out other causes. Seek prompt assessment if you have:
- Any bleeding after menopause — including spotting after sex — should be medically evaluated; do not assume it's from atrophy alone
- Pain that's localized to one specific spot that doesn't move — possible vestibulodynia or focal vulvodynia
- Visible white patches, ulcers, or non-healing lesions on the vulva — possible lichen sclerosus, lichen planus, or vulvar precancer
- Vulvar skin changes — whitening, thickening, cracks, loss of normal anatomy, or recurrent tearing — get examined rather than assuming it's simple dryness
- Deep pelvic pain with thrusting that's worse in certain positions — possible endometriosis, fibroids, or prolapse
- Pain not improving after 8-12 weeks of vaginal estrogen — needs reassessment
- Pain accompanied by foul-smelling discharge — likely infection
- Pain plus burning urination, frequent UTIs — GSM cluster, but should still rule out infection and bladder pathology
- Pelvic floor that won't relax — pelvic PT evaluation needed
- History of sexual trauma with pelvic-floor guarding — coordinated medical and psychological care
What You Can Do About It
A staged approach is the standard of care. Most women benefit from doing several at once.
Quick Reference: Treatment Options for Painful Sex in Menopause
| Treatment | Form | When to use | Note |
|---|---|---|---|
| Vaginal estrogen (cream / tablet / ring) | Local hormonal | First-line for GSM dyspareunia | Multiple FDA-approved options |
| Vaginal DHEA (prasterone, Intrarosa) | Daily insert | GSM + modest libido benefit | FDA-approved for dyspareunia |
| Ospemifene (Osphena) | Oral SERM | Oral preference; can't use intravaginal | FDA-approved |
| Lubricants (water- or silicone-based) | OTC, as-needed | Immediate relief for sex | Adjunct, not curative |
| Vaginal moisturizers (hyaluronic acid) | OTC, 2-3×/week | Mild GSM; non-hormonal preference | Builds tissue moisture; not just for sex |
| Vaginal dilators + pelvic floor PT | Behavioral | Pelvic floor dysfunction component | Esp. post-childbirth / post-cancer |
| Sex therapy / couples therapy | Behavioral | Relationship / anxiety contributors | Cognitive-behavioral approach |
Immediate strategies for sex itself
- Use a high-quality, iso-osmolar lubricant — water- or silicone-based, applied generously to both partner and self before and during sex; reapply as needed. Avoid products with warming, tingling, or flavoring 5, and beware of high-osmolality lubricants (many traditional drugstore brands) which can actually draw moisture out of already-dry vaginal tissue
- Allow more time for arousal — atrophic tissue produces less natural transudate, so external arousal needs more time
- Change positions — positions that let you control depth and angle, such as being on top or side-lying
- Use a vaginal moisturizer regularly (every 1-3 days, not just at intercourse) — restores baseline tissue moisture, separate from sex-specific lubricant
- Topical lidocaine (selectively) — some clinicians recommend topical lidocaine for selected patients with pain focused at the vaginal opening, especially when vestibular tenderness is part of the picture. 4% formulations are OTC; 5% require prescription. Because it can irritate tissue or numb a partner, ask your clinician how and when to use it
- Don't push through pain — pain reinforces the muscle-tension cycle; stop, reposition, or pause
Restoring tissue health
- Low-dose bioidentical vaginal estradiol — first-line prescription treatment for GSM-related dyspareunia 1, 2. Cream, tablet, or ring. Improvement begins in 2-4 weeks, full effect at 8-12 weeks. Concierge BHRT practices typically prescribe FDA-approved bioidentical estradiol (identical to what the body produces), which is generally preferred over older synthetic or animal-derived estrogens (e.g., conjugated equine estrogens). Unlike systemic estrogen therapy, low-dose vaginal estrogen does not raise blood estrogen levels enough to stimulate the uterine lining, so a separate progesterone/progestin is not required for endometrial protection. Systemic absorption is low; these products treat vaginal/urinary symptoms rather than whole-body menopause symptoms. Women with a history of estrogen-sensitive cancer should review options with their treating clinicians
- Prasterone (Intrarosa®) 3 — a nightly vaginal DHEA insert, FDA-approved for moderate-to-severe dyspareunia due to menopause-related vulvovaginal atrophy
- Hyaluronic-acid vaginal moisturizers — a nonhormonal option with some supportive evidence; some women do well with these alone or in combination with hormonal therapy
- Ospemifene (Osphena®) 4 — an oral SERM (selective estrogen receptor modulator) that has estrogen-like effects in some tissues. FDA-approved specifically for moderate-severe dyspareunia. Important safety note: Ospemifene carries an FDA boxed warning for endometrial cancer (estrogenic effect on the uterus) and increased risk of blood clots and stroke, similar to systemic estrogens. It is not appropriate for everyone and requires careful screening — particularly in women with unexplained vaginal bleeding, a history of blood clots, stroke risk factors, or known/suspected estrogen-dependent cancer
- Vaginal dilators — graduated devices used progressively to gently restretch the vagina, especially valuable if penetrative sex has been infrequent for a long time. Vaginal dilators can help gradually restore comfort and flexibility over time, especially when pain has led to avoidance. Many women need guidance from a pelvic floor therapist or clinician
- Systemic hormone therapy — may help if you also have symptoms like hot flashes, but it does not always fully treat GSM; some women still need vaginal estrogen or another local therapy
Beyond the tissue
- Pelvic floor physical therapy — for women with hypertonic pelvic floor muscles, targeted PT can relieve the muscle component of dyspareunia. Often essential when atrophy treatment isn't enough
- Sex therapy — for women whose sexual confidence has eroded, or for couples managing the relational impact. Can be the difference between "physically better" and "back to enjoying intimacy"
- Couples communication — partner involvement matters; education about what helps, what hurts, and what to try is part of treatment
- Mind-body approaches — mindfulness, paced breathing, and CBT have evidence for reducing the anxiety-tension cycle
Lifestyle factors that genuinely help
- Regular sexual activity (alone or with a partner) — improves vaginal blood flow and tissue health
- Stop smoking — accelerates atrophy
- Avoid harsh soaps, douches, scented products — disrupt the vulvar microbiome and worsen irritation
- Wear cotton underwear, avoid tight pants if symptomatic
Get Started with JumpstartMD
Painful sex is treatable — and one of the most rewarding symptoms to treat.
JumpstartMD's perimenopause and menopause care is part of our broader Total Health Optimization approach — a medically-supervised bioidentical hormone therapy program delivered by an expert team of licensed clinicians (under physician oversight), supported by lifestyle coaching for the behavioral side of care. Treatment balances five key hormones — estrogen, progesterone, DHEA, testosterone, and thyroid — through pills, creams, patches, injections, or subcutaneous pellet therapy (in-person visits only).
The program follows a structured pathway: a phone connection with our team, an online health questionnaire, comprehensive hormone labs at Quest Laboratories, a clinical consultation to review results, a personalized treatment plan, and regular follow-ups to fine-tune dosing as your body responds. Care is delivered in-person at our 14 California clinics or online from anywhere in California. When weight or metabolic health is contributing to your symptoms, BHRT is coordinated with our medical weight loss program in the same care plan.
Membership benefits include comprehensive lab testing, ongoing support and monitoring, exclusive member pricing on products, and concierge medical insurance claims assistance for PPO out-of-network plans (FSA/HSA accepted).
Book FREE Consultation
Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.
Frequently Asked Questions
Can I use vaginal estrogen as a lubricant right before sex?
No. Vaginal estrogen is a tissue-restoring medication, not a personal lubricant. Applying it right before sex can be messy, cause friction irritation, and transfer hormone to your partner. Apply estrogen at bedtime as directed; use a separate water- or silicone-based lubricant during intercourse. When estrogen is used at night as directed, the risk of hormonal transfer to a partner during sex the next day is negligible.
How long should I try lubricants and moisturizers before adding hormones?
If you're using a vaginal moisturizer regularly (every 1-3 days) and a quality lubricant during sex, and pain hasn't improved after 4-6 weeks, that's typically the time to add low-dose vaginal estrogen. Severe or longstanding atrophy almost always requires hormone treatment to restore tissue health — moisturizer alone cannot reverse the structural changes.
Will sex feel "normal" again with treatment?
For most women with GSM as the dominant cause, yes. Tissue health, lubrication, and elasticity substantially recover with low-dose vaginal estrogen, often returning sexual comfort to pre-perimenopausal levels. The recovery takes 8-12 weeks for full effect.
For women with vulvodynia, lichen sclerosus, or pelvic floor dysfunction as primary or contributing causes, recovery requires treating those conditions specifically. Combined treatment is highly effective, but the timeline is longer.
Is the pain worse if I haven't had sex in a while?
Often, yes. Sexual activity (alone or partnered) increases vaginal blood flow and helps maintain tissue elasticity. Women who haven't had penetrative sex for months or years may find the vaginal opening has narrowed, making first attempts more painful. Vaginal dilators address this directly — gentle, graduated stretching restores comfortable penetrative function over 6-8 weeks. Treatment with vaginal estrogen for 4-8 weeks before resuming sex is also commonly effective.
Can my partner help?
Yes — partner involvement is part of effective treatment. Open communication about what feels good, what hurts, and what's being tried (lubricant, position changes, dilators) reduces anxiety on both sides. For couples where the pain has affected the relationship, sex therapy with a certified therapist can be invaluable. Some women find their partners are relieved to learn this is a treatable medical condition, not a sign of declining attraction or relationship problems.
Why was I only told to use lubricant?
Some clinicians under-prioritize GSM symptoms or assume women already know about the prescription options. If your symptoms haven't improved with OTC products and your provider hasn't offered to evaluate further or prescribe vaginal estrogen / prasterone / ospemifene, seek a second opinion from a clinician with menopause expertise (the Menopause Society Certified Practitioner credential is one signal). Treatment options have expanded significantly in the last decade.
References
- The North American Menopause Society, "The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society," Menopause, vol. 27, no. 9, pp. 976-992, Sep. 2020, [Online]. Available: https://doi.org/10.1097/GME.0000000000001609. PMID: 32852449. [Accessed: Apr. 26, 2026]. ↩
- D. Edwards, N. Panay, "Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?," Climacteric, vol. 19, no. 2, pp. 151-161, 2016, [Online]. Available: https://doi.org/10.3109/13697137.2015.1124259. PMID: 26707589. [Accessed: Apr. 26, 2026]. ↩
- U.S. Food and Drug Administration, "Highlights of Prescribing Information: Intrarosa (prasterone) vaginal inserts," [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208470s000lbl.pdf. [Accessed: Apr. 26, 2026]. ↩
- U.S. Food and Drug Administration, "Highlights of Prescribing Information: Osphena (ospemifene) tablets," [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203505s014lbl.pdf. [Accessed: Apr. 26, 2026]. ↩
- American College of Obstetricians and Gynecologists, "Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213," Obstetrics & Gynecology, vol. 134, no. 1, pp. e1-e18, Jul. 2019, PMID: 31241598. [Accessed: Apr. 26, 2026]. ↩
- The North American Menopause Society, "The 2022 hormone therapy position statement of The North American Menopause Society," Menopause, vol. 29, no. 7, pp. 767-794, Jul. 2022, [Online]. Available: https://doi.org/10.1097/GME.0000000000002028. PMID: 35797481. [Accessed: Apr. 26, 2026]. ↩